The new GLP-1 liver cancer study found fewer liver-cancer diagnoses in people with type 2 diabetes and recorded viral hepatitis. Hepatitis means liver inflammation; here, it referred to hepatitis B or C. The study doesn't prove that these medicines prevent cancer. It also cannot answer for everyone taking a GLP-1 for weight loss.
GLP-1 medicines copy a gut hormone involved in appetite and blood sugar. The finding gives researchers a reason to investigate liver outcomes more closely. It doesn't replace treatment for hepatitis or an individual's cancer-screening plan.
What the GLP-1 liver cancer study found
As of November 5, 2026, the day this article was written, a study published online October 27 in Clinical and Molecular Hepatology adds evidence in a specific group. Xinrong Zhang and colleagues examined U.S. insurance claims from 2013–2022 for adults with type 2 diabetes and chronic hepatitis B, C, or both.
They matched people with similar recorded histories, leaving 9,499 patients: 2,133 GLP-1 users and 7,366 people not using these medicines. The comparison group could receive other diabetes treatments. This was observational research: researchers compared existing records rather than assigning medicines by chance.
The cancer measured was hepatocellular carcinoma, the most common cancer starting in the liver. Cirrhosis means advanced liver scarring. Each outcome analysis excluded people who already had that diagnosis. A hazard ratio compares how quickly an outcome occurs during follow-up; 1 means no difference.
The table shows diagnoses per 1,000 person-years, meaning 1,000 combined years of patient follow-up.
| Outcome | GLP-1 users | People not using GLP-1 medicines | Hazard ratio |
|---|---|---|---|
| Liver cancer | 3.09 | 6.36 | 0.53 |
| Cirrhosis | 30.60 | 47.43 | 0.70 |
For cancer, that's roughly 3 diagnoses versus 6 in that much observation time.
The cancer estimate of 0.53 represents a 47% lower relative hazard, not 47 fewer cancers per 100 people. Its 95% confidence interval, the estimate's uncertainty range, was 0.31–0.93.
What it means for diabetes and hepatitis care
The finding concerns people managing two conditions together. It raises a useful question about choosing diabetes treatment when viral hepatitis is also part of someone's medical history.
It doesn't answer that question for an individual. A prescriber still weighs blood sugar, weight, existing liver damage, other medicines, and side effects. The study did not compare a GLP-1 with hepatitis treatment or test whether it could replace one.
Viral hepatitis and fatty liver are different diagnoses, though they can occur together. The separate semaglutide fatty-liver evidence concerns MASH, an inflammatory form of fatty liver disease. A result about liver fat or inflammation doesn't establish fewer cancers, either.
Hepatitis C and hepatitis B gave different answers
The associations were clearer among people recorded as having hepatitis C. The hepatitis B-only group did not show a statistically clear reduction in the measured outcomes. Neither did the smaller group recorded as having both infections.
That uncertainty does not establish that GLP-1 medicines work differently against the two viruses. Smaller groups and fewer diagnoses make a difference harder to detect.
The records also lacked blood-test results showing whether the virus remained active. Some hepatitis C diagnoses could represent previously treated infection. That limits how precisely the finding applies to someone's current hepatitis status.
Does this establish an Ozempic or tirzepatide benefit?
The headline belongs to a medicine class. Researchers pooled dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide. The semaglutide-only liver-cancer estimate was inconclusive. Calling the pooled result an Ozempic cancer-prevention benefit would overstate it.
Tirzepatide wasn't one of the five medicines analyzed. It acts on GLP-1 and a second gut-hormone signal involved in blood sugar. That connection does not let it inherit this study's result. Its separate fatty-liver research asks a different question.
The choice of comparison also mattered. GLP-1 users had lower liver-cancer rates than people starting DPP-4 inhibitors, diabetes medicines that prolong the body's own hormone signals. There was no statistically clear difference against SGLT-2 inhibitors, medicines that help the kidneys remove sugar. That finding establishes neither superiority nor equivalence between those treatments.
Why the result still doesn't prove prevention
Matching can balance recorded medical histories. It cannot account for everything that affects who receives a medicine or develops cancer. The database lacked detailed diet, physical activity, laboratory, and race or ethnicity information. It also covered insured people.
Follow-up for the cancer analysis was typically about two years. Cancer can take much longer to develop. One additional analysis that delayed follow-up by six months no longer showed a statistically clear cancer association.
Earlier evidence also cautions against a sweeping conclusion. A Scandinavian study in Hepatology, 2024 found fewer serious liver events with GLP-1 medicines than with DPP-4 inhibitors, driven by fewer cirrhosis events. Its liver-cancer comparison was inconclusive. That study excluded people with recorded chronic liver diseases other than fatty liver, so it cannot settle the viral-hepatitis question.
The separate pancreatic-cancer study concerns another organ and another question. Findings about one cancer cannot answer for all cancers.
What this changes about a prescription
As of November 5, 2026, the day this article was written, GLP-1 medicines are not FDA-approved to prevent liver cancer. The FDA-posted Wegovy label, marked “Revised: 06/2026,” lists treatment for a defined group with MASH, which is different from cancer prevention. The Zepbound label, marked “Revised: 08/2026,” doesn't list liver-cancer prevention either.
Through Promise, semaglutide and tirzepatide are dispensed by a licensed U.S. compounding pharmacy as compounded medications. This is different from an FDA-approved product: the formulations offered here are not FDA-approved.
The FDA explains that these preparations do not undergo its review for safety, effectiveness, or quality before marketing. This records study does not establish outcomes for a compounded formulation.
A licensed provider may still prescribe — that decision is between you and your doctor.
What to watch next
The next useful evidence would separate individual medicines, confirm whether hepatitis is active or treated, and follow people longer. Randomized trials, which assign treatment by chance, would help test whether the medicine itself accounts for the association.
Meanwhile, the American Association for the Study of Liver Diseases' guidance identifies antiviral treatment, medicine targeting the hepatitis virus, as a way to reduce liver-cancer risk. For people who meet screening criteria, it recommends ultrasound and a blood test about every six months. This new finding provides no basis for replacing that care.
At Promise, a licensed provider reviews every request, and not everyone qualifies. A visit can consider the actual liver diagnosis and treatment goal alongside the evidence.
